Inherited hepatocellular carcinoma

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 5, 2010, Pages 725-734

  Villanueva, Augusto ^a,b   Newell, Pippa ^c   Hoshida, Yujin ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Oregon Clinic   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Clinical management; Hereditary haemochromatosis; Liver cancer

Indexed keywords

AFLATOXIN B; BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN;

ALCOHOL ABUSE; ALCOHOL LIVER CIRRHOSIS; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; GAUCHER DISEASE; GENE MUTATION; GENETIC DISORDER; GENETIC LINKAGE; GENOTYPE ENVIRONMENT INTERACTION; GLYCOGEN STORAGE DISEASE TYPE 1; HEMOCHROMATOSIS; HEREDITARY HEMACHROMATOSIS; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; NONALCOHOLIC FATTY LIVER; PHLEBOTOMY; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL RADIOEMBOLIZATION; TUMOR RECURRENCE; VIRUS HEPATITIS;

EID: 77958094944     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2010.07.008     Document Type: Article

References (73)

1. A. Sangiovanni, E. Del Ninno, and P. Fasani Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance Gastroenterology 126 2004 1005 1014
2. H.B. El-Serag Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 2004 S27 S34
3. M.H. Chang, C.J. Chen, and M.S. Lai Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 1997 1855 1859
4. Y.F. Liaw, J.J. Sung, and W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
5. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
6. J.A. Marrero, R.J. Fontana, and G.L. Su NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 2002 1349 1354
7. B.Q. Starley, C.J. Calcagno, and S.A. Harrison Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 2010 1820 1832
8. B. Bressac, M. Kew, and J. Wands Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Nature 350 1991 429 431
9. G.S. Qian, R.K. Ross, and M.C. Yu A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China Cancer Epidemiol Biomarkers Prev 3 1994 3 10
10. M. Sherman Vinyl chloride and the liver J Hepatol 51 2009 1074 1081
11. A.L. Fracanzani, D. Conte, and M. Fraquelli Increased cancer risk in a cohort of 230 patients with hereditary haemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease Hepatology 33 2001 647 651
12. A. Pietrangelo Hereditary hemochromatosis - a new look at an old disease N Engl J Med 350 2004 2383 2397
13. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
14. F. Jin, L.S. Qu, and X.Z. Shen Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis J Exp Clin Cancer Res 29 2010 18
15. M. Pirisi, P. Toniutto, and A. Uzzau Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients Cancer 89 2000 297 302
16. T. Taddei, P. Mistry, and M.L. Schilsky Inherited metabolic disease of the liver Curr Opin Gastroenterol 24 2008 278 286
17. H. Iwadate, H. Ohira, and T. Suzuki Hepatocellular carcinoma associated with Wilson's disease Intern Med 43 2004 1042 1045
18. N.C. Birch, S. Radio, and S. Horslen Metastatic hepatocellular carcinoma in a patient with niemann-pick disease, type C J Pediatr Gastroenterol Nutr 37 2003 624 626
19. R. Xu, P. Mistry, and G. McKenna Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature Semin Liver Dis 25 2005 226 229
20. C. Andant, H. Puy, and J.C. Deybach Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria Am J Gastroenterol 92 1997 1389 1390
21. M. Branda, and J.R. Wands Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma Hepatology 43 2006 891 902
22. M.A. Feitelson, and J. Lee Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis Cancer Lett 252 2007 157 170
23. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687
24. A. Villanueva, P. Newell, and D.Y. Chiang Genomics and signaling pathways in hepatocellular carcinoma Semin Liver Dis 27 2007 55 76
25. Y. Hoshida, S. Toffanin, and A. Lachenmayer Molecular classification and novel targets in hepatocellular carcinoma: recent advancements Semin Liver Dis 30 2010 35 51
26. A. Villanueva, S. Toffanin, and J.M. Llovet Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps Curr Opin Oncol 20 2008 444 453
27. Y. Hoshida, A. Villanueva, and M. Kobayashi Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
28. P. Legoix, O. Bluteau, and J. Bayer Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity Oncogene 18 1999 4044 4046
29. A. Villanueva, D.Y. Chiang, and P. Newell Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983 1983 e1-11
30. P. Newell, S. Toffanin, and A. Villanueva Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733
31. V. Tovar, C. Alsinet, and A. Villanueva IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage J Hepatol 52 2010 550 559
32. P. Kaposi-Novak, J.S. Lee, and L. Gomez-Quiroz Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 2006 1582 1595
33. D. Semela, and J.F. Dufour Angiogenesis and hepatocellular carcinoma J Hepatol 41 2004 864 880
34. A. Villanueva, B. Minguez, and A. Forner Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy Annu Rev Med 61 2010 317 328
35. D.Y. Chiang, A. Villanueva, and Y. Hoshida Focal gains of VEGFA and molecular classification of hepatocellular carcinoma Cancer Res 68 2008 6779 6788
36. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
37. M. Sherman Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis Semin Liver Dis 30 2010 3 16
38. R. Iannaccone, A. Laghi, and C. Catalano Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis Radiology 234 2005 460 467
39. A. Forner, R. Vilana, and C. Ayuso Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
40. A. Forner, M.E. Reig, and C.R. de Lope Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
41. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
42. J.A. Marrero, R.J. Fontana, and A. Barrat Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 716
43. J.M. Croswell, and B.S. Kramer Clinical trial design and evidence-based outcomes in the study of liver diseases J Hepatol 50 2009 817 826
44. P.M. Lopez, A. Villanueva, and J.M. Llovet Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials Aliment Pharmacol Ther 23 2006 1535 1547
45. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
46. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
47. K. Hasegawa, M. Makuuchi, and T. Takayama Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey J Hepatol 49 2008 589 594
48. P.M. Lopez, A. Villanueva, and S. Roayaie Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal Liver Transpl 12 2006 1747 1754
49. M.S. Chen, J.Q. Li, and Y. Zheng A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann Surg 243 2006 321 328
50. T. Livraghi, F. Meloni, and M. Di Stasi Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47 2008 82 89
51. K.D. Fairbanks, and A.S. Tavill Liver disease in alpha 1-antitrypsin deficiency: a review Am J Gastroenterol 103 2008 2136 2141 quiz 2142
52. S.A. Harrison, and B.R. Bacon Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention Med Clin North Am 89 2005 391 409
53. K.F. Kok, P.J. Wahab, and R.H. Houwen Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review Neth J Med 65 2007 160 166
54. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
55. V. Mazzaferro, J.M. Llovet, and R. Miceli Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
56. B. Minguez, Y. Hoshida, and A. Villanueva Molecular gene signature to identify vascular invasion in hepatocellular carcinoma Hepatology 48 2008 386A
57. J.M. Llovet, M. Schwartz, and V. Mazzaferro Resection and liver transplantation for hepatocellular carcinoma Semin Liver Dis 25 2005 181 200
58. G.C. Sotiropoulos, E.P. Molmenti, and H. Lang Surgery for hepatocellular carcinoma arising in hereditary hemochromatosis Eur Surg Res 38 2006 371 376
59. S. Landen, E. Bardaxoglou, and F. Derbel Surgical management of hepatocellular carcinoma in genetic haemochromatosis Acta Chir Belg 94 1994 307 310
60. H. Pleass, and O.J. Garden Early diagnosis of hepatocellular carcinoma in haemochromatosis influences surgical management Scott Med J 43 1998 114 115
61. F.J. Farrell, M. Nguyen, and S. Woodley Outcome of liver transplantation in patients with hemochromatosis Hepatology 20 1994 404 410
62. K.V. Kowdley, T. Hassanein, and S. Kaur Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis Liver Transpl Surg 1 1995 237 241
63. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
64. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
65. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
66. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
67. M. Varela, M.I. Real, and M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
68. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
69. S.M. Wilhelm, L. Adnane, and P. Newell Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
70. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
71. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
72. C.C. Jaffe Measures of response: RECIST, WHO, and new alternatives J Clin Oncol 24 2006 3245 3251
73. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249